POSB105 Budget Impact Analysis of Introduction of Subcutaneous Infliximab in France from a Payer Perspective

Abstract

Authors

M Pradie C Hadjadj F Petiteau Moreau

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×